Resveratrol alleviates bleomycin-induced lung injury in rats
PULMONARY PHARMACOLOGY & THERAPEUTICS, cilt.20, sa.6, ss.642-649, 2007 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 20 Sayı: 6
- Basım Tarihi: 2007
- Doi Numarası: 10.1016/j.pupt.2006.07.003
- Dergi Adı: PULMONARY PHARMACOLOGY & THERAPEUTICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.642-649
- Anahtar Kelimeler: bleomycin, resveratrol, fibrosis, cytokine, lipid peroxidation, glutathione, IDIOPATHIC PULMONARY FIBROSIS, ORAL N-ACETYLCYSTEINE, MYELOPEROXIDASE ACTIVITY, MECHANISMS, DAMAGE, INFLAMMATION, PROTECTION, CYTOKINES, MELATONIN, SEPSIS
- Marmara Üniversitesi Adresli: Evet
Özet
Antioxidant therapy may be useful in diseases with impaired oxidant-antioxidant balance such as pulmonary fibrosis. This study was designed to examine the effects of resveratrol, an antioxidant agents, against bleomycin-induced pulmonary fibrosis and oxidative damage. Wistar albino rats were administered a single dose of bleomycin (5 mg/kg; via the tracheal cannula) followed by either saline or resveratrol (10 mg/kg; orally) for 14 days. The effect of resveratrol on pulmonary oxidative damage was studied by cell count and analysis of cytokine levels (TGF-beta, TNF-alpha, IL-1 beta and IL-6) in the bronchoalveolar lavage fluid (BALF) and biochemical measurements of malondialdehyde (MDA), an end product of lipid peroxidation; glutathione (GSH), a key antioxidant; and myeloperoxidase (MPO) activity, an index of neutrophil infiltration, in the lung tissue.